BioFire Diagnostics, LLC
Active in EUDAMEDUnited Statesfrom SRN EUDAMED FDA SRN US-MF-000003311 FEI 3002773840
BioFire Diagnostics, LLC is a medical device manufacturer based in the United States, with 87 devices listed in FDA GUDID, FDA 510(k) and EUDAMED (FDA Class II and Unclassified; EU Class B and D) and 47 FDA recalls as of 18 Nov 2026.
- Devices
- 87
- Registrations
- EUDAMEDFDA
- FDA recalls
- 4730 ongoing
Registry facts
- Registries
- FDA GUDID 46
- FDA 510(k) 38
- EUDAMED 19
- Device classes
- FDA Class II 81
- FDA Unclassified 3
- EU Class B 2
- EU Class D 1
- Top EMDN categories
- Reagents 3
- FDA recalls
- Identifiers
- EUDAMED SRN US-MF-000003311
- FDA FEI 3002773840
- DUNS 079280262
At a glance
EU certificates
3 of 3 in force.
Market reach
- European Union
- EUDAMED actor, 3 certificates
- United States
- FDA FEI, FDA recalls
Catalogue
Search and filter all 87 devicesShowing 1-50 of 87
Company details
- EUDAMED SRN
- US-MF-000003311
- FDA FEI number
- 3002773840
- DUNS number
- 079280262
- EUDAMED status
- Active
- EUDAMED registered name
- BioFire Diagnostics, LLC
- Registered address
- 515, Colorow Drive, 84108, Salt Lake City, United States
- PRRC contact
- Eric Scott
EUDAMED certificates
3 certificates3 valid, 0 expiredIVDR 3next expiry 6 May 2031
BSI Group The Netherlands B.V. 2797 3 certificates
- IVDR 799673 Active
Technical documentation EU IVDR
- Issued
- 3 Aug 2026
- Expires
- 2 Aug 2031
- IVDR 799675 Active
Technical documentation EU IVDR
- Issued
- 3 Aug 2026
- Expires
- 2 Aug 2031
- IVDR 735494 Active
Quality management system EU IVDR
- Issued
- 3 Aug 2026
- Expires
- 6 May 2031
- Reason
- Add device or group
FDA recalls
Recalls initiated per year
- 2017 0
- 2018 3
- 2019 3
- 2020 2
- 2021 8
- 2022 0
- 2023 13
- 2024 8
- 2025 3
- 2026 6
2026
- 12 Aug 2026 Z-0148-2027 Class II Ongoing Due to potential contaiminated of spefic lots of pneumonia and joint infection panels that could result in false positive results
Full distribution text
- 12 Aug 2026 Z-0149-2027 Class II Ongoing Due to potential contaiminated of spefic lots of pneumonia and joint infection panels that could result in false positive results
Full distribution text
- 12 Aug 2026 Z-0150-2027 Class II Ongoing Due to potential contaiminated of spefic lots of pneumonia and joint infection panels that could result in false positive results
Full distribution text
- 24 Jun 2026 Z-2936-2026 Class II Ongoing Due to increase in false negative results
- 22 Apr 2026 Z-2067-2026 Class II Ongoing Contamination to in-vitro diagnostic test may result in false positives.
Full distribution text
- 1 Apr 2026 Z-2081-2026 Class II Ongoing Respiratory/sore throat panel test may result in false negative results and control failures.
- 12 Aug 2026 Z-0148-2027 Class II Ongoing Due to potential contaiminated of spefic lots of pneumonia and joint infection panels that could result in false positive results
2025
- 22 Oct 2025 Z-0602-2026 Class II Ongoing Due to unintended movement of pouch chemistry, nucleic acid test may result in elevated risk of false negative results and risk of control failures.
- 30 Apr 2025 Z-1877-2025 Class II Ongoing Due to manufacturing error, respiratory panel may result in elevated control failures and/or false negative results.
- 27 Feb 2025 Z-1518-2025 Class II Ongoing Increased risk of control failures and false negative test results with multiplexed nucleic acid test.
2024
- 7 Aug 2024 Z-3122-2024 Class II Ongoing Some automated in vitro diagnostic modules and instruments manufactured or serviced between May 2022 and May 2024 were calibrated with internal equipment that may lead modules and instruments to report higher melting temperatures, which may lead to erroneous results including false positive Salmonella, Giardia lamblia, false positive/negative Norovirus, and false negative MRSA.
Full distribution text
- 7 Aug 2024 Z-3122-2024 Class II Ongoing Some automated in vitro diagnostic modules and instruments manufactured or serviced between May 2022 and May 2024 were calibrated with internal equipment that may lead modules and instruments to report higher melting temperatures, which may lead to erroneous results including false positive Salmonella, Giardia lamblia, false positive/negative Norovirus, and false negative MRSA.
Show the 25 most recent of 47 recalls
2024
- 7 Aug 2024 Z-3123-2024 Class II Ongoing Some automated in vitro diagnostic modules and instruments manufactured or serviced between May 2022 and May 2024 were calibrated with internal equipment that may lead modules and instruments to report higher melting temperatures, which may lead to erroneous results including false positive Salmonella, Giardia lamblia, false positive/negative Norovirus, and false negative MRSA.
Full distribution text
- 19 Jun 2024 Z-2456-2024 Class II Ongoing If blood culture identification panel is used in conjunction with specific lots of culture media bottles, then false positive Serratia marcescens results may occur, due to an increased level of non-viable organism from serratia marcescens targets in culture media bottles, false positive result may lead to an inappropriate change in patient therapy.
Full distribution text
- 10 Jun 2024 Z-2682-2024 Class II Ongoing Pneumonia panels have an increased risk of control failures due to an issue in the manufacturing process, which could lead to delayed results for the customer.
Full distribution text
- 10 Jun 2024 Z-2683-2024 Class II Ongoing Pneumonia panels have an increased risk of control failures due to an issue in the manufacturing process, which could lead to delayed results for the customer.
Full distribution text
- 16 May 2024 Z-2514-2024 Class II Ongoing Due to increase of false positive Vibrio/Vibrio Cholerae results when using a certain transport medium.
Full distribution text
- 26 Jan 2024 Z-1139-2024 Class II Ongoing Due to a trend in false positive Candida tropicalis results on blood culture panel when using certain BD BACTEC vial mediums
Full distribution text
- 26 Jan 2024 Z-1140-2024 Class II Ongoing Due to potential signals of increased false positive Norovirus results when using the gastrointestinal (GI) panel.
Full distribution text
- 7 Aug 2024 Z-3123-2024 Class II Ongoing Some automated in vitro diagnostic modules and instruments manufactured or serviced between May 2022 and May 2024 were calibrated with internal equipment that may lead modules and instruments to report higher melting temperatures, which may lead to erroneous results including false positive Salmonella, Giardia lamblia, false positive/negative Norovirus, and false negative MRSA.
2023
- 14 Dec 2023 Z-0993-2024 Class II Ongoing Their is a potential for false positive results when using Pneumonia panel.
Full distribution text
- 14 Dec 2023 Z-0994-2024 Class II Ongoing Their is a potential for false positive results when using Pneumonia panel.
Full distribution text
- 27 Nov 2023 Z-0703-2024 Class II Ongoing A manufacturing event may contribute to elevated rates of false negative results while using gastrointestinal panel and respiratory panel, which could lead to inappropriate antibiotic treatment, no treatment, delay of treatment, and may provide false assurance to someone with a true infection, delayed identification of an outbreak, and may result in additional transmission.
- 27 Nov 2023 Z-0704-2024 Class II Ongoing A manufacturing event may contribute to elevated rates of false negative results while using gastrointestinal panel and respiratory panel, which could lead to inappropriate antibiotic treatment, no treatment, delay of treatment, and may provide false assurance to someone with a true infection, delayed identification of an outbreak, and may result in additional transmission.
- 17 Oct 2023 Z-0353-2024 Class II Ongoing Due to an increased risk of degradation of the power entry switch resulting from arcing inside of the power switch that may result in carbon build-up on the switch contacts. The carbon build-up may lead to excess heating inside of the power switch, subsequently leading to deformation of the power switch case. The deformation can create an opportunity for a power switch electrical short. In addition to an electrical short, deformation may result in an open circuit causing the power switch to fail. This event would only occur after the product is in use.
Full distribution text
- 17 Oct 2023 Z-0451-2024 Class II Ongoing Routine quality control testing of affected blood culture identification panel with affected control panel may need to be amended, due to control panel/instrument characteristic changes, that lead C. tropicalis to be amplified in some portion of test runs, but then it's reported as "Not Detected" because the assay amplicon Tm is outside the acceptable limit assigned for calling positive results.
Full distribution text
- 8 May 2023 Z-2439-2023 Class II Ongoing Due to manufacturing issue, panels may result in false negative results.
Full distribution text
- 8 May 2023 Z-2440-2023 Class II Ongoing Due to manufacturing issue, panels may result in false negative results.
Full distribution text
- 14 Dec 2023 Z-0993-2024 Class II Ongoing Their is a potential for false positive results when using Pneumonia panel.
Frequently asked questions
How many devices does BioFire Diagnostics, LLC have in the registry?
The registry currently lists 87 devices for BioFire Diagnostics, LLC. Devices recorded under merged duplicate company entries are counted once.
Which registries list BioFire Diagnostics, LLC's devices?
Among its 50 most recently registered devices, BioFire Diagnostics, LLC has devices listed in EUDAMED (19 devices), FDA 510(k) (1 device) and FDA GUDID (46 devices). A device can be listed in more than one registry, so these counts overlap.
What risk classes do BioFire Diagnostics, LLC's devices fall under?
Among its 50 most recently registered devices, the classes recorded for BioFire Diagnostics, LLC's devices are Class II, IVDR Class B and IVDR Class D. Each device page shows its own class and authorisation.
Are there FDA recall records for BioFire Diagnostics, LLC?
FDA recall records list 47 recalls initiated by BioFire Diagnostics, LLC, the most recent initiated on 12 Aug 2026. 30 of them are recorded as ongoing. A recall is often a precaution started by the manufacturer; the records say nothing about the company's overall record.
What EUDAMED certificates are recorded for BioFire Diagnostics, LLC?
EUDAMED lists 3 certificates for BioFire Diagnostics, LLC (technical documentation; quality management system) under IVDR. 2 are recorded with the status issued. The most recent was issued on 3 Aug 2026.
What are the newest devices from BioFire Diagnostics, LLC in the registry?
The most recently registered devices listed for BioFire Diagnostics, LLC include BIOFIRE FILMARRAY GI1.1 Panel, BIOFIRE Respiratory Panel 2.1 (RP2.1), BioFire® Respiratory Panel 2.1 plus (RP2.1 plus) and FilmArray® 2.0 Instrument FLM2-ASY-0001.